It’s the end of the year – which means it’s time for year-end round-ups! As is our tradition, we publish our recommendation report card every year. Here, we take a look at how Prime Funds, our mutual fund recommendations, performed.

Prime finds performance in 2023

In Prime Funds, we look for consistency in performance compared to the category and/or the benchmark, ability to contain losses, and variety in strategy. We do not always have the top performer in the category or the 5-star funds because of the priority we place on these factors. That means, sometimes, you may see low-rated funds or seeming underperformers featuring in the list. But that doesn’t mean it’s not a fund to own! Barring short-term fund categories, calls we take in Prime Funds are always done keeping in view the long-term nature of most portfolios and that markets move in cycles.

Now let’s move on to how we did, lest you think we’re trying to justify ourselves too early!

Prime Funds – Equity

2023 was the age of small-caps in equity markets. While the large-cap segment had rapidly climbed back over the second half of 2022, the small cap stocks were yet to recover. But that story turned right around with the small and midcap segment rallying at a breathtaking pace over the course of the year.

In Prime Funds, our learnings from watching the rapid shifts in sector and stock movements and overall market movements over the past 3 years have led us to modify our approach. As we documented in our 2022 performance review, our intention in Prime Funds was to: 

  • Become more dynamic in introducing funds without waiting for multiple quarters of outperformance in order to catch the rally early on. 
  • Become stricter with underperformers. 

Changes we undertook over 2023 in Prime Funds have been in keeping with this approach, and to introduce a strategy variety in the funds. Here’s how our picks did.

In this set of Prime Funds, we draw from the large-cap, flexi-cap, value/contra and focused categories. We look for ability to beat the large-cap indices consistently, since these funds are primarily large-cap oriented. This is one bucket where we typically make the least changes, since our picks are steady long-term performers. We have, however, added funds here last quarter for the following reasons:

  • To introduce more variety in fund strategy, especially with slightly more aggressive funds to include some higher-return options. 
  • With the large-cap segment getting more broad-based than the narrow rally earlier, large-cap oriented funds are becoming better able to beat the Nifty 100. This opens up more options now to add active large-cap based funds to a portfolio. 
  • To gear up for more opportunities in the large-cap segment in the event of a market correction or should large-caps try to catch up to the rest of the market.

Here’s how the Equity – Moderate Prime Funds did on an average in 2023:

Prime Funds beat the Nifty 100 TRI by a comfortable margin. However, the returns are marginally lower than the category average. This is for the following reasons:

  • The value/contra category has seen a very strong year. The Prime Funds set has funds from growth-oriented funds as well that have seen more tepid returns. That has marginally impacted the overall Prime Funds returns.
  • A key drag was Mirae Asset Large Cap, a fund whose underperformance we have been highlighting in our quarterly reviews as well. Excluding this fund brings the average returns up to 29.7%. We have been watching the Mirae’s fund performance; the extent of underperformance is currently not steep and the fund has a solid performance history. The fund has also gone through bouts of underperformance earlier. This apart, it is a pure large-cap fund (and the only one from the large-cap category in Prime Funds) that may find it harder to beat funds from other categories that could include mid-cap picks as well. We will continue to watch the fund's performance and take action if necessary.

This set of Prime Funds features funds that have a high allocation to mid-and-small caps. They come from a wide variety of categories – other than large-caps, any category is game for inclusion here! This set does not have only pure small-cap or pure mid-cap funds. We do this mix to avoid having too many highly volatile funds and because there is not much choice in pure mid-caps or small caps. A mix is also useful to allow investors across risk profiles add higher-returning funds to their portfolio without going to the small-cap basket. In this Prime Funds bucket, we prize downside containment and volatility here over just returns.

This Prime Funds set has seen more frequent changes than the Moderate set over 2023 as we overhauled it to remove drags and add more options in a rallying market. Here’s how this set performed:

This is one bucket of Prime Funds where we are unsatisfied with our overall performance. The Prime Funds beat the broad-market Nifty 500 by a good margin, and this is fine given the wide variety of funds in this category. However, the set has lagged the average of the key categories from which we build these recommendations. We had a hard time with being cautious in the runaway mid-and-smallcap rally in terms of quality of fund portfolios while still trying to include aggressive performers to add high-returning options.

Primarily, the lower returns compared to the category average are due to the following factors:

  • The category average is lifted by the very strong returns of the smallcap segment. The Nifty Smallcap 250 TRI delivered about 45% in 2023. However, Prime Funds – Aggressive features only 3 pure small-cap funds. In addition, of these 3, SBI Smallcap was an underperformer. We had retained it because of its prudent strategy and quality history; these funds form part of long-term portfolios – we did not want to simply add the top-returning funds given the extremely rapid rise of the stocks in the smallcap segment. We added HDFC Smallcap mid-year as its performance was turning around. The same holds with our mid-cap picks such as Kotak Emerging Equity and Mahindra Manulife Midcap that are otherwise solid performers that took a backseat in this rally.
  • The biggest drags here were PGIM Flexicap and PGIM Midcap Opportunities. In fact, removing these two funds lifts the Prime Funds average to 35.2%. We had added both funds in 2022 given their strong portfolio quality. However, a drop in performance widened through the year; despite sound stock picks, early exits and underperforming sectors weighed on returns. Both funds also saw a fund manager change. We removed the midcap fund owing to steep underperformance compared to the Nifty Midcap 150. We have retained the flexicap fund, since longer-term performance was intact and the new fund manager has a history of turning around performance. We will continue to watch performance and make changes if necessary.
  • There were two other long-time Prime Funds we removed as underperformance widened which were Mirae Asset Emerging Bluechip and SBI Focused Equity.  

Overall, in this Prime Funds set, we do see the need to include more aggressive or opportunistic funds. However, we will also need to balance this against the current market exuberance. Our aim is to pick funds that will not disproportionately hurt portfolio returns should markets correct and which will still deliver strong returns over time. We have become stricter now with underperformers than we were earlier as well, and that has helped us maintain the better options in Prime Funds.

We have been more active in adding to thematic recommendations this year. We issued specific calls on commodities in February, healthcare in May, banking in August, consumption in August, IT in September. These calls were also added to Prime Funds Strategy & Thematic set as soon as we issued them. The thematic set features themes that are:

  • Tactical plays to build on markets favouring a theme such as healthcare and commodities. DSP Healthcare and UTI Transportation & Logistics are two such Prime Funds that have played out very well this year.
  • Contrarian or given when sectors are down, such as banking and IT. We further added one more IT fund to the Prime Funds list, as its portfolio offered a different set of stocks from the other IT funds.
  • Long-term potential such as consumption. 

Overall, thematic Prime Funds returned an average of 27.6% in 2023 compared to the Nifty 500’s 23.9%.

Prime Funds – Hybrid

Hybrid funds are an extremely wide-ranging set that have different allocations to equity, debt, derivatives (and gold and other commodities in multi-asset funds). In Prime Funds, we split these between low and moderate risk based on funds’ equity allocations. In 2023, we also added a couple more funds to our hybrid recommendations to offer more variety for those looking to replace debt funds post the tax change in April 2023. 

For the Moderate Risk Hybrid Funds set, here’s how performance shaped up in 2023.

On the whole, our recommendations have beaten the category average. Of course, a couple of our picks Quant Absolute and Canara Robeco Equity Hybrid, weren’t necessarily the chart toppers but both funds have managed to hold up performance. Quant Absolute saw lower returns owing to sticking to very short-term debt papers even as other hybrid aggressive funds used dipping yields to their advantage and generated good returns from their debt portfolios. In fact, removing this fund lifts the average Prime Funds returns to 22.5%.

Our picks such as ICICI Equity & Debt, ICICI Multi-Asset and Edelweiss Balanced Advantage have all beaten their categories. We also added HDFC Balanced Advantage to introduce another hybrid fund that actively manages both equity and debt.

Prime Funds – Debt

Debt funds came in for a shock taxation change in 2023 that saw their long-term indexation benefits taken away for investments made after April 1st, 2023. While this certainly impacts returns, we still think that debt funds are an essential component to any portfolio. They offer return opportunities that cannot be found in equity markets and are good diversifiers. Low-risk hybrid funds are not debt funds – they will still move based on equity markets - and cannot be used to replace debt entirely. 

With this view, we have not changed our approach to debt funds in Prime Funds. We have been issuing strategic recommendations when rate cycles and yields throw up opportunities – as we have done several times especially over 2022 – and will add or remove funds based on performance and rates. We continue to recommend that you add debt funds to your portfolio based on your timeframe.

Fund performance and yields had been picking up over the past year after the long low-rate cycle suppressed debt fund returns across the board. Government bond yields also dipped for a while this year on lower inflation expectations and this helped several long-maturity funds notch up some gains.

We had also adopted a more positive view on credit as the economy picks up and on improving credit quality in 2022. We continued to hold that view over 2023 as well and even added a couple of funds in shorter-maturity buckets that took marginal exposure to credit for better returns.

In this, we made very few changes. The Bharat Bond April 2023 target maturity fund was merged into the 2025 fund as it neared maturity. We removed Nippon India Money Market and added HDFC Low Duration as portfolio yields were marginally higher in other funds. since these funds are meant for very short holding periods, going for quality funds that offer even a little higher yield would work well. Here’s how performance of this Prime Funds segment fared. Remember that even small return differentials are significant in the debt category.  

All our picks did better than the category average. Funds such as Aditya Birla SL Floating Rate Fund and Aditya Birla SL Money Manager were especial good performers with average 2023 return of 7.3%. 

In this Prime Funds set, we have made a few changes to bring in better portfolio yields and to prepare for any rate cut cycle that may play out next year. For example, we removed the Bharat Bond April 2025 target maturity fund as other short duration funds offered better yields. We added ICICI Banking & PSU debt fund to gain from a rate cut cycle and due to the fund’s ability to deftly juggle its portfolio to play different maturities and instruments. Here's how this Prime Funds set fared against the category:

Our approach of picking from different fund categories and using portfolio build and maturity to categorise & recommend funds has helped us pick varied opportunities and beat the category average. The two floating rate funds in Prime Funds, for example, managed a 2023 return of 7.15% and 7.51%. The marginal credit in HDFC Short Term helped higher returns.

Here, we have bunched together our Medium Term and Long Term Prime Funds, since there are similarities in funds and because all suit timeframes of more than 3 years. In these sets, we tried to introduce specific fund strategies given that long-maturity funds were hit with a double whammy – the long low-rate period up to 2022 saw portfolio yields and returns stay low. The rate hike cycle in 2022 then pushed down bond prices and that in turn hit returns. 

While these do offer good investing opportunities, we also tried to introduce funds that could work even in these markets through funds that shifted between maturities to play yield opportunities. Here is how performance has fared compared to category:

On the whole, Prime Funds beat the average for long-maturity debt categories. As mentioned above, we added ICICI Pru Gilt, a fund that shifted between maturities in gilts as yield movements were rangebound. This paid off well and the fund is among the best performers in this set. Our other gilt constant maturity fund has also done very well, gaining from the let up in yields. Our other corporate bond picks have by and large also stayed above category average. In the long-term bucket, ICICI Credit Risk has also done very well. A pick that didn’t quite match up is Edelweiss Banking & PSU Debt fund for its long-maturity portfolio with steady roll-down, as a tactical play given the rate cycle. However, a drop in returns gave us pause and we removed it in our September review. 

In Prime Funds, overall, we will continue with our current approach. Our quarterly review of all our recommendations helps us spot brewing performance issues early on and take action where necessary. Based on market scenarios, we also alert you on specific opportunities even within Prime Funds. We will publish our 2024 outlook for equity and debt markets in January; based on our assessment and how markets shape up, we will issue strategy or tactical calls when necessary. So do keep an eye out! 

More like this

15 thoughts on “Prime Funds performance in 2023”

  1. Anandkumar Mehta

    Dear team

    Does the underperformance of Kotak Emerging worry you? Last 1 year, this fund has under performed benchmark and category by 10% which is very, very significant. I understand the pedigree of the fund but how do I justify to myself sticking to a fund that delivered such an underperformance in a red hot market? Appreciate if you can elaborate what reasons you think that drives the underperformance and how long to wait for before making a decision to switch?

    Thanks
    Anand

    1. Hello Sir, Please read tomorrow’s Prime Funds review and you will find why we are waiting it out. thanks, Vidya

  2. venkataraman.balaji

    Hello,
    Thanks for the year review.
    You have flagged and removed SBI Focused Equity Fund from Prime Funds. Should I hold or sell? Pl. clarify.

    1. We have a Hold call on the fund. You can use Portfolio Review Pro to see a one-shot view of our Buy/Sell/Hold calls, or use the old MF Review Tool. We are working on building a new alert system that will let you know if our calls on funds you hold have changed. This will make it easier for you to keep track as well. – thanks, Bhavana

  3. Thank you for the transparent annual review and the details.

    Was the call to remove PGIM Midcap Opportunities from prime funds too late? How do you really asses the new fund manager’s history of turning things around in the past would work promptly before we run out of patience? One more example of a similar kind: are we too quick to introduce HDFC Flexicap now, given that there was such a significant change at the fund management level?

    Also, how are real-time (hence relevant) calls buy vs. hold calls? For example, I see a buy call of Quant Active vs a hold call for Quant Flexi cap fund. Maybe it should be the other way, given the current small-cap rally.

    1. No, it is always a balance between allowing short-term underperformance owing to calls taken in a portfolio and pulling out a fund for underperformance. It’s usually clear in hindsight only – when we make such calls, we look at the portfolio quality, what has led to the underperformance, can it turn around etc. We pulled the fund out because the lag was getting too steep for a short-term recovery. As far as fund managers go – we know how funds they managed earlier have done, the manner in which those funds’ performance has changed etc. Not sure what you mean by real-time calls – our calls are reviewed every quarter, and we make these based on performance trends relative to index and peers, market scenario etc. – thanks, Bhavana

  4. More Rigirous and quicker scrutiny of the receomended funds need to be done, our portfolios are based on your receomendations

    1. We understand. We review Prime Funds every quarter to make sure that we catch underperformance or other opportunities early on.

      To clarify, though, frequently taking out funds for a few quarters’ underperformance will result in too many funds in your portfolio or too much churn. We therefore always try to gauge the reason for underperformance and potential for recovery before removing. Prime Funds in general are those that beat category/benchmark with a good degree of consistency – they are not always the top funds but they do deliver. Do note that the returns picture above is for the year 2023 alone. – thanks, Bhavana

  5. And every time an underperforming fund is dropped, the number of funds one carries keeps increasing (for example, PGIM midcap is dropped and let us say, you take on another ‘performing’ midcap, that will mean 2 funds, now instead of 1 in your list)….and every review will point that I am carrying too many funds…over the years, so many underperformers were dropped but it takes a long long time to go off the list…and at any point of time, I carry 5-7 of these at any given time

    1. Yes, we understand your point and see the problem of fund changing resulting in too many funds in a portfolio.

      We definitely do keep that in mind when reviewing Prime Funds. And usually, our churn across Prime Funds is not high – we add more than we remove – because the metrics we use to pick funds mean that most are steady performers. We have only been a little more active with shorter-term debt funds.

      But in equity especially, market conditions made a big difference and we needed to change our own approach in the past couple of years. The sector/stock movements have been quick or sharp, and unless a fund caught it quick it tended to lose. There have been pockets where quality of stocks that were rallying also dipped. So funds that follow a more long-term or fundamental approach were left lagging. We initially allowed this underperformance, since portfolio quality was solid. But underperformance also deepened significantly and in our experience, it can take a very long time for a fund to recover from huge lags. For these reasons, we became stricter and looked to remove & replace funds that were lagging too much.

      In active funds, it will call for some amount of active management of a portfolio…that is par for the course and the nature of market and fund performance now also means one needs to gear up for a bit more scrutiny. – thanks, Bhavana

  6. Good review and good performance but here are some finer aspects. An underperforming fund, say PGIM Midcap being dropped doesn’t mean, magically, it will change the performance of the PF of a subscriber. The reason is, once a fund is dropped from Prime PF, it takes an year or 3 (for ELSS or older debt) to go off the PF of the subscriber. At best, one can stop the SIP and nothing else !!

  7. Thank You … Appreciate if you can publish periodically REAL-TIME and 1/2/3/4/5 year CAGR performance of your Stock recommendations …

    1. Stock returns are real-time…if you click on ‘More details’ next to the stock on Prime Stocks, you will find updated returns. Giving 1/3/5 year returns is not really representative of our performance; we cannot claim a 5-year returns of a stock that we issued a call on 2 months ago as performance, for example. So we don’t do that. – thanks, Bhavana

Comments are closed.

Hold On

You are being redirected to another page,
it may take a few seconds.
Login to your account
OR

Become a PrimeInvestor!

Get stock & mutual fund recommendations

Start registration

Start registration

OR
user icon
user icon
user icon

Terms & Conditions

A copy of the T&C has been sent to your email.

Last modified on February 18, 2025

This website www.primeinvestor.in (“Website”) is owned and operated by PrimeInvestor Financial Research Pvt. Ltd. (“RA”), a SEBI-registered Research Analyst with Registration No. INH200008653.

Through the Website, the RA allows clients to access research recommendations, research reports, and model portfolios, along with tools, personal finance products, and articles, on the payment of a subscription fee (“Research Services”). The terms ‘RA’ or ‘us’ or ‘we’ refer to PrimeInvestor Financial Research Pvt Ltd (SEBI RA Registration No INH200008653) who are the owners of this Website and offering the Research Services. The term ‘you’ and ‘client’ refers to the subscriber of the Services on the Website. The RA provides the Research Services subject to the notices, terms, and conditions set forth in these Terms. By accepting these Terms when you subscribe to the Research Services, you provide your consent to abide by these Terms.

Most Important Terms and Conditions (MITC)

[Forming part of the Terms and Conditions for providing research services]

  1. These terms and conditions, and consent thereon are for the research services provided by the Research Analyst (RA) and RA cannot execute/carry out any trade (purchase/sell transaction) on behalf of the client. Thus, the clients are advised not to permit RA to execute any trade on their behalf.
  2. The fee charged by RA to the client will be subject to the maximum amount prescribed by SEBI/ Research Analyst Administration and Supervisory Body (RAASB) from time to time (applicable only for Individual and HUF Clients).
    Note:
    • SEBI's current cap on fee is Rs 1,51,000/- per annum per family of client for all research services of the RA.
    • The fee limit does not include statutory charges.
    • The fee limits do not apply to a non-individual client / accredited investor.
  3. RA may charge fees in advance if agreed by the client. Such advance shall not exceed the period stipulated by SEBI; presently it is one quarter. In case of pre-mature termination of the RA services by either the client or the RA, the client shall be entitled to seek refund of proportionate fees only for the unexpired period.
  4. Fees to RA may be paid by the client through any of the specified modes like cheque, online bank transfer, UPI, etc. Cash payment is not allowed. Optionally the client can make payments through Centralized Fee Collection Mechanism (CeFCoM) managed by BSE Limited (i.e. currently recognized RAASB).
  5. The RA is required to abide by the applicable regulations/ circulars/ directions specified by SEBI and RAASB from time to time in relation to disclosure and mitigation of any actual or potential conflict of interest. The RA will endeavor to promptly inform the client of any conflict of interest that may affect the services being rendered to the client.
  6. Any assured/guaranteed/fixed returns schemes or any other schemes of similar nature are prohibited by law. No scheme of this nature shall be offered to the client by the RA.
  7. The RA cannot guarantee returns, profits, accuracy, or risk-free investments from the use of the RA's research services. All opinions, projections, estimates of the RA are based on the analysis of available data under certain assumptions as of the date of preparation/publication of research report.
  8. Any investment made based on recommendations in research reports are subject to market risks, and recommendations do not provide any assurance of returns. There is no recourse to claim any losses incurred on the investments made based on the recommendations in the research report. Any reliance placed on the research report provided by the RA shall be as per the client's own judgement and assessment of the conclusions contained in the research report.
  9. The SEBI registration, Enlistment with RAASB, and NISM certification do not guarantee the performance of the RA or assure any returns to the client.
  10. For any grievances,
    • Step 1: the client should first contact the RA using the details on its website or following contact details:
      Customer care: [email protected]
      Grievance officer: [email protected], ATTN: Srikanth Meenakshi
      Compliance officer: [email protected], ATTN.: Bhavana Acharya
      Principal officer: [email protected], ATTN.: Vidya Bala
    • Step 2: If the resolution is unsatisfactory, the client can also lodge grievances through SEBI's SCORES platform at www.scores.sebi.gov.in
    • Step 3: The client may also consider the Online Dispute Resolution (ODR) through the Smart ODR portal at https://smartodr.in
  11. Clients are required to keep contact details, including email id and mobile number/s updated with the RA at all times.
  12. The RA shall never ask for the client’s login credentials and OTPs for the client’s Trading Account, Demat Account, and Bank Account. Never share such information with anyone including RA.

By browsing, viewing, using the Website and subscribing to the Research Services provided therein you consent to and agree to comply with these Terms and Conditions of subscription (“Terms”).

The RA reserves the right to change or modify the Website, the contents thereof and these Terms at any time. All modifications to these Terms & Conditions will be posted on the Website and will become effective immediately upon such posting. Changes once made will be communicated to the client. Continued use of the Website shall be construed as acceptance of the revisions to the Terms by conduct.

The following terms and conditions include but are not limited to minimum mandatory terms and conditions to clients as stipulated by SEBI.

1. Availing the research services

By accepting delivery of the research service, the client confirms that he/she has elected to subscribe to the research service of the RA at his/her sole discretion. The RA confirms that Research Services shall be rendered in accordance with the applicable provisions of the SEBI RA Regulations.

2. Obligations on RA

The RA shall be bound by the SEBI Act and all the applicable rules and regulations of SEBI, including the RA Regulations and relevant notifications of Government, as may be in force, from time to time.

3. Client Information and KYC

The client shall furnish all such details in full as may be required by the RA in its standard form with supporting details, if required, as may be made mandatory by Research Analyst Administration and Supervisory Body(RAASB)/SEBI from time to time. RA shall collect, store, upload and check KYC records of the clients with KYC Registration Agency (KRA) as specified by SEBI from time to time.

4. Standard Terms of Service

The consent of client shall be taken on the following understanding:

“I / We have read and understood the terms and conditions applicable to a research analyst as defined under regulation 2(1)(u) of the SEBI (Research Analyst) Regulations, 2014, including the fee structure.

I/We are subscribing to the research services for our own benefits and consumption, and any reliance placed on the research report provided by research analyst shall be as per our own judgement and assessment of the conclusions contained in the research report.

I/We understand that –

  1. Any investment made based on the recommendations in the research report are subject to market risk.
  2. Recommendations in the research report do not provide any assurance of returns.
  3. There is no recourse to claim any losses incurred on the investments made based on the recommendations in the research report.”

The declaration of the RA is as follows:

  1. We are duly registered with SEBI as an RA pursuant to the SEBI (Research Analysts) Regulations, 2014 and our registration details are: registration no SEBI INH200008653, with registration date 19th August, 2021
  2. We have the registration and qualifications required to render the services contemplated under the RA Regulations, and the same are valid and subsisting;
  3. Research analyst services provided by us do not conflict with or violate any provision of law, rule or regulation, contract, or other instrument to which it is a party or to which any of its property is or may be subject;
  4. The maximum fee that may be charged by the RA is ₹1.51 lakhs per annum per family of client. Our current fee structure, the term and duration of our subscription for our Research Services, can be viewed on our website here: https://primeinvestor.in/prime-pricing
  5. The recommendations provided by us as part of the Research Services do not provide any assurance of returns.

5. Consideration and mode of payment

The client shall duly pay to the RA the agreed fees for the services that RA renders to the client and statutory charges, as applicable. Such fees and statutory charges shall be payable through the specified manner and mode(s)/ mechanism(s).

The payment of fees shall be through a mode that shows traceability of funds. Such modes include but are not limited to credit cards/debit cards/ UPI/ net banking or any other mode specified by SEBI from time to time. However, the fees shall not be in cash.

6. Risk factors

  1. Investments are subject to market risk. Investing or trading in financial products involves risk. Past performance of the recommendation is not an indication of future returns. Past performance of the RA is not an indicator of future performance. Past performance of the security is not an indication of future returns.
  2. There are no assurances or guarantees that the objectives of any investment in financial products will be achieved.
  3. The names of financial products mentioned herein do not in any manner indicate their prospects or returns. The performance in the equity may be adversely affected by the performance of individual companies, changes in the market place and industry specific and macro-economic factors.
  4. The performance of the investments/ products recommended by the RA are subject to a wide range of risks, including but not limited to: performance of the respective companies, changes in equity and debt market conditions, micro and macro factors and forces affecting equity and debt markets, general levels of interest rates and interest rate risk, credit risk, liquidity risk, reinvestment risk, economic slowdown, volatility & illiquidity of the stocks, risks associated with trading volumes, liquidity and settlement systems in equity and debt markets and/or such other circumstance beyond the control of the RA or any of its Associates.
  5. Other risk factors include that may affect the performance of the investments/ products recommended by the RA include but are not limited to economic policies, changes of Government and its policies, acts of God, acts of war, civil disturbance, sovereign action and /or such other acts/ circumstance beyond the control of the RA or any of its Associates.
  6. The recommendations provided by the RA as part of its Research Services may not be suitable to all categories of investors.
  7. The client should read all scheme and security related documents carefully before investing.
  8. Returns and performance figures mentioned in the research report represent past performance and should not be constituted to be future returns or guaranteed returns.

7. Conflict of interest

The RA shall adhere to the applicable regulations/ circulars/directions specified by SEBI from time to time in relation to disclosure and mitigation of any actual or potential conflict of interest. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

General disclosures: PrimeInvestor Financial Research Pvt Ltd (with brand name PrimeInvestor) is an independent research entity offering research services on personal finance products to customers. We are a SEBI registered Research Analyst (Registration: INH200008653). PrimeInvestor Financial Research Pvt. Ltd., its employees, directors or agents, do not have any material adverse disciplinary history as on the date of publication of this report.

Restrictions on trading: To ensure no conflict of interest, the RA declares as follows:

  1. Personal trading activities of the individuals employed as research analysts shall be monitored, recorded and subject to a formal approval by the directors or compliance officer of PrimeInvestor Financial Research Private Limited.
  2. Research analysts employed by PrimeInvestor Financial Research Private Limited or their associates or relatives shall not:
    • Deal/ trade in stocks recommended/ tracked by the research analyst within 30 days before and five days after the publication of a research report;
    • Deal/ trade in securities that the research analyst reviews in a manner contrary to the given recommendation;
    • Purchase or receive securities of the issuer before the issuer's initial public offering, if the issuer is principally engaged in the same types of business as companies that the research analyst follows or recommends.

Disclosures with respect to Research and Recommendations Services:

  1. The RA or its directors or any of its officer/employee does not trade in securities which are subject matter of recommendation.
  2. The RA, or any of its officers, directors, employees, or subsidiaries have not received any compensation/ benefits whether monetary or in kind, from the AMC, company, government, bank or any other product manufacturer or third party, whose products are the subject of its Research Services or investment information.
  3. The Research Analysts who have prepared the research reports that form part of the Research Services (“Research Analyst”) certify that all of the views expressed in the research report accurately reflect their views about the subject company or subject security.
  4. The RA or directors or employees or Research Analyst certify that no part of their compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.
  5. The Research Analyst has not served as director, officer or employee in the subject company, AMC or insurance company of the mutual fund or insurance policy that is the subject of this report, or company whose bonds, NCDs, fixed deposits or other savings products that is the subject of this report.
  6. The Research Analyst or their relatives do not have any known direct or indirect material conflict of interest including long/short positions in the subject company.
  7. The Research Analyst may hold investments in the stocks, mutual fund schemes, bonds, fixed deposits, insurance policies, or other products that are the subject of the recommendations provided as part of the Research Services. The Research Analyst certifies that they will not act in a manner contrary to their views on these securities except in the event of significant news or event or change in personal financial circumstances and without formal approval from the directors of PrimeInvestor Financial Research Pvt. Ltd. or the compliance officer.
  8. There are no actual or potential conflicts of interest arising from any connection to or association with any issuer of products/ securities, including any material information or facts that might compromise its objectivity or independence in the carrying on of the Research Services. Such conflict of interest shall be disclosed to the client as and when they arise.
  9. The RA or its directors or its employee or its associates have not managed or co-managed the public offering of any company. The RA or its directors or its employee or its associates have not received any compensation for investment banking or merchant banking of brokerage services from the subject company. The RA or its directors or its employee or its associates have not received any compensation for products or services other than above from the subject company. The RA or its directors or its employee or its associates have not received any compensation or other benefits from the Subject Company or 3rd party in connection with the research report/ recommendation.
  10. The subject company of its research recommendations was not a client of the RA or its directors or its employee or its associates during twelve months preceding the date of recommendation services provided.
  11. The RA or its directors or its employee or its associates has not served as an officer, director or employee of the subject company. Research Analysts has not been engaged in market making activity of the subject company.

PrimeInvestor Financial Research Pvt. Ltd., its Associates, the Research Analysts or their relatives holds ownership of 1% or more, in respect of the said issuer company(ies)? – NO

8. Termination of service and refund of fees:

The RA may terminate or suspend rendering of Research Services to the client in the following circumstances:

  1. On account of suspension/cancellation of registration of RA by SEBI. In case of suspension of certificate of registration of the RA for more than 60 (sixty) days or cancellation of the RA registration, RA shall refund the fees, on a pro rata basis for the period from the effective date of cancellation/ suspension to end of the client’s subscription period.
  2. The RA voluntarily chooses to terminate its Research Service. In the event of such termination of the Research Service, the RA shall refund the fees, on a pro rata basis for the period from the date of such termination of research service to end of the client’s subscription period.

9. Grievance redressal and dispute resolution:

Any grievance related to:

  1. nonreceipt of research report, or
  2. missing pages or inability to download the entire report, or
  3. any other deficiency in the research services provided by RA

shall be escalated promptly by the client to the person/employee designated by RA, in this behalf as under:

Name: Bhavana Acharya
Designation: Director & Compliance Officer, PrimeInvestor Financial Research Pvt Ltd
Email: [email protected]

The RA shall be responsible to resolve grievances within 7 (seven) business working days or such timelines as may be specified by SEBI under the RA Regulations.

RA shall redress grievances of the client in a timely and transparent manner. Any dispute between the RA and his client may be resolved through arbitration or through any other modes or mechanism as specified by SEBI from time to time.

If the client is not satisfied with the response of the RA, he/she can lodge his/her grievances with SEBI at scores.sebi.gov.in. Alternatively, the client may also write to any of the offices of SEBI. For any queries, feedback or assistance, please contact SEBI Office on Toll Free Helpline at 1800 22 7575 / 1800 266 7575

Details on grievances are available on the Website as follows: https://primeinvestor.in/ra-grievance/

10. Additional clauses:

Scope of the Research Service: The Research Services will be limited to providing independent research recommendation and shall not be involved in any advisory or portfolio allocation services. The Research Services are not meant to be tailor-made or customized solutions that specifically apply to each client based on his/her risk profile.

The RA never guarantees the returns on the recommendation provided. Investor shall take note that investment/trading in stocks/Index or other securities is always subject to market risk. Past performance is never a guarantee of same future results. The RA shall not be responsible for any loss to the Investors.

This service is not directed for access or use by anyone in a country, especially the USA, Canada or the European Union countries, where such use or access is unlawful or which may subject PrimeInvestor Financial Research Pvt Ltd or its affiliates to any registration or licensing requirement.

The Research Service, including recommendations, research reports, updates, and other information will be accessible through the RA’s website https://primeinvestor.in only. Such recommendations and updates will not be provided over phone calls.

Fees: Our current fee structure, the term and duration of our subscription for our Research Service, can be viewed on our website: https://primeinvestor.in/prime-pricing. Eligibility for any discounts is ascertained at the time the client subscribes. Any such discount and its tenure shall be at the discretion of the RA.

Subscription and access to content services fall under the purview of Goods and Services Tax (GST) as per the current indirect taxation policy, Government of India. Unless otherwise indicated, prices stated on our website are exclusive of applicable GST, any applicable value added tax (VAT) or other sales taxes. We are a business-to-consumer (B2C) service provider and we do not commit to provide any input tax credit on GST charged on subscription to our Research Service.

We may change the Subscription Fees and charges then in effect, or add new fees or charges which will take effect at the end of the client’s subscription period, by giving notice in advance and an opportunity to cancel renewal of the subscription.

Subscription Access & Renewal: Subscription to the Website commences immediately on the realisation of payment of the Subscription Fees. Subscriptions are set to be renewed automatically at the end of the subscription period.

Unless the client notifies us before the end of his/her subscription period, or the client cancels the auto-renewal mandate within the period specified by law, that the client does not wish to renew his/her subscription, the client’s subscription will renew for the period defined by the client’s subscription plan. We will charge the subscription using the same payment method that you previously used.

Although the client may notify to us his/her intention to his/her subscription, such notice will only take effect at the end of his/her then current subscription period, and he/she will not receive a refund other than as set out under Clause 8 in these Terms.

The client may notify us of his/her wish to cancel his/her subscription by sending an email to [email protected]. The client must provide at least 5 business days advance notice for this to be implemented.

Refunds: There can be no cancellation and refund of subscription fee paid once the subscription is active, other than as stated in Clause 8 of these Terms. If the client is entitled to a refund as specified under Clause 8 of these Terms, the RA will credit that refund to the card or other payment method used by the client to submit payment, unless it has expired - in which case the RA will contact the client to proceed with the refund. If we do issue a refund or credit due to circumstances outside the obligations specified under Clause 8, we are under no obligation to issue the same or a similar refund in the future.

General disclaimers: The recommendations made herein in the Research Services are expression of views and/or opinions and should not be deemed or construed to be advice for the purpose of purchase or sale of any security, nor a solicitation or offering on any investment/ trading opportunity on behalf of the company, AMC, insurance company, or issuer of security referred to herein.

The content and research reports generated by the RA does not constitute or is not intended to constitute an offer to buy or sell, or a solicitation to an offer to buy or sell financial products, units or securities.

The information/ opinion/ views mentioned in research reports or by the RA are not meant to serve as a professional guide to the client or recipients of this Report. The research report, recommendation, or any other content published by the RA do not assure or guarantee any minimum or fixed returns to the client or recipients of the reports/ recommendations/ content.

Use of this information is at the client’s own risk. The client must make his/ her own investment decisions based on his/her specific investment objective and financial position and using such independent advisors as he/she believes necessary. The services rendered by the RA are on a best-effort basis. All information in the content or research report of the RA is provided on an as is basis. Information is believed to be reliable but the RA does not warrant its completeness or accuracy and expressly disclaim all warranties and conditions of any kind, whether express or implied.

While due care has been taken to ensure that the disclosures, information, and opinions given are fair and reasonable, PrimeInvestor Financial Research Pvt Ltd and/or none of its officers, directors, partners, employees, agents, subsidiaries, affiliates or business associates shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information/ opinions/ views contained in the research report and recommendations that form part of the Research Service, and/or mails, social media or notifications issued by PrimeInvestor Financial Research Pvt Ltd or any other agency appointed/authorised by PrimeInvestor Financial Research Pvt Ltd. Returns and performance figures mentioned in the research report represent past performance and should not be constituted to be future returns or guaranteed returns.

Any agreements, transactions or other arrangements made between the client and any third party named on (or linked to from) the Website are at your own responsibility and entered into at your own risk. Any information that you receive via the Website, whether or not it is classified as “real time”, may have stopped being current by the time it reaches you. Market price information may be rounded up/down and therefore may not be entirely accurate.

The purpose of these disclosures is to provide essential information about the Research Services in a manner to assist and enable the prospective client/client in making an informed decision for engaging in Research Services before onboarding.

History, present business and background: PrimeInvestor Financial Research Private Limited is registered with SEBI as Research Analyst with registration no. INH200008653. The Research Analyst got its registration on August 19, 2021 and is engaged in offering research and recommendation services.

Disciplinary history: There are no pending material litigations or legal proceedings against the Research Analyst. As on date, no penalties / directions have been issued by SEBI under the SEBI Act or Regulations made thereunder against the Research Analyst relating to Research Analyst services.

Details of the RA's associates: No associates.

Usage of Website Content: This Website is controlled and operated by the RA. All material, including research reports, recommendations, portfolios, ratings, lists of financial products, illustrations, statements, opinions, views, photographs, products, images, artwork, designs, text, graphics, logos, button icons, images, audio and video clips and software (collectively, “Content”) are protected by copyrights, trademarks and other intellectual property rights that are owned and controlled by the RA or by other parties that have licensed their material to us.

Except where otherwise agreed in writing with the RA, material on the Website is solely for the client’s personal, non-commercial use. Except as provided below, the client must not copy, reproduce, republish, upload, post, transmit or distribute such material in any way, including by e-mail or other electronic means and whether directly or indirectly and the client must not assist any other person to do so.

Without the prior written consent of the RA, modification of the materials, use of the materials on any other web site or networked computer environment or use of the materials for any purpose other than personal, non-commercial use is a violation of the copyrights, trademarks and other proprietary rights, and is prohibited. Any use for which the client receives any remuneration, whether in money or otherwise, is a commercial use for the purposes of these Terms.

The client may occasionally distribute a copy of a research report, or a portion of the same, from the Website in non-electronic form to a few individuals without charge, provided the client includes all copyright and other proprietary rights notices in the same form in which the notices appear, original source attribution, and the phrase “Used with permission from PrimeInvestor Financial Research Pvt. Ltd.”

While the client may occasionally download and store research reports or information from the Website for his/her personal use, he/she may not otherwise provide others with access to the same. The foregoing does not apply to any sharing functionality we provide through the Website that expressly allows the client to share Content or links to Content with others. In addition, the client may not use Content he/she has downloaded for personal use to develop or operate an automated trading system or for data or text mining.

The client agrees not to rearrange or modify the Content available through the Website. The client agrees not to display, post, frame, or scrape the Content for use on another website, app, blog, product or service, except as otherwise expressly permitted by these Terms. You agree not to create any derivative work based on or containing the research products and Content. The framing or scraping of or in-line linking to the Services or any Content contained thereon and/or the use of webcrawler, spidering or other automated means to access, copy, index, process and/or store any Content made available on or through the Services other than as expressly authorized by us is prohibited.

The client further agrees to abide by exclusionary protocols (e.g., Robots.txt, Automated Content Access Protocol (ACAP), etc.) that may be used in connection with the Research Services. The client may not access parts of the Research Services to which he/she is not authorized, or attempt to circumvent any restrictions imposed on your use or access of the Services.

As a general rule, the client may not use the Content, including without limitation, any Content made available through one of our RSS Feeds, in any commercial product or service, without our express written consent.

The client may not create apps, extensions, or other products and services that use our Content without our permission. The client may not aggregate or otherwise use our Content in a manner that could reasonably serve as a substitute for a subscription to the Website.

The client may not access or view the Services with the use of any scripts, extensions, or programs that alter the way the Services are displayed, rendered, or transmitted to you without our written consent.

The client agrees not to use the Services for any unlawful purpose. We reserve the right to terminate or restrict the client's access to the Website if, in our opinion, the client's use of the Services may violate any laws, regulations or rulings, infringe upon another person's rights or violate these Terms.

Prohibited content: The Website includes comments sections, blogs and other interactive features that allow interaction among clients and between clients and the RA. We call the information posted by or contributed by users “Contributed Content.” In the course of availing of the Research Services or uploading any post or comment on the Website, the client shall not post any Contributed Content that (i) contains nude, semi-nude, sexually suggestive photos, (ii) tends or is likely to abuse, harass, threaten, impersonate or intimidate other users of the Website and/or Research Services, (iii) is lascivious or appeals to the prurient interest or if its effect is such as to tend to deprave and corrupt persons who are likely to use or have access to the Website and/or Services, or (iv) otherwise violates, is prohibited or restricted by applicable law, rule or regulation, is offensive or illegal or violates the rights of, harms or threatens the safety of other users of the Website and/or Services (collectively “Prohibited Content”).

We reserve the right to cease to provide the client with the Research Services or access to the Website, or terminate your subscription, with immediate effect and without notice and liability, for violating these Terms, applicable law, rules or regulations and reserves the right to remove Prohibited Content which is in violation of these Terms, or is otherwise abusive, illegal or disruptive. The determination of whether any content constitutes Prohibited Content, violates these Terms, or is otherwise abusive illegal or disruptive, is subject to the sole determination of the Firm.

Changes to Research Services: We are constantly endeavouring to improve the quality of Research Services provided to our clients. Due to this, the form and nature of the Research Services provided may change from time to time without any prior notice to the client. We reserve the right to introduce and initiate new features, functionalities, components to the Website and/or Research Services and/or change, alter, modify, or discontinue existing ones without any prior notice to the client.

Warranty and liability disclaimer: The Website, Research Services, and all the materials and services, included on or otherwise made available to the client through this Website is provided by the RA on an “as is” and “as available” basis without any representation or warranties, express or implied except otherwise specified in writing. Without prejudice to the foregoing paragraph, the RA does not warrant that:

  • This Website and/or Research Services will be constantly available, or available at all;
  • The information on this Website or provided through the Research Services is complete, true, accurate or not misleading; or
  • The quality of any products, services, information, or other material that you obtain through the Website or Services will meet your expectations.

The RA, to the fullest extent permitted by law, disclaims all warranties, whether express or implied, including the warranty of merchantability, fitness for particular purpose and non-infringement. The RA makes no warranties about the accuracy, reliability, completeness, or timeliness of the Website, Research Services, Content, Contributed Content, Services, software, text, graphics and links.

The RA does not warrant that this Website, Research Services, information, content, materials, or any other material included on or otherwise made available to you through this Website, their servers, or electronic communication sent by the RA are free of viruses or other harmful components.

Nothing on this Website constitutes, or is meant to constitute, advice of any kind.

Indemnification: The client:

  1. Represents, warrants and covenants that no materials of any kind provided by him/her will:
    1. Violate, plagiarise, or infringe upon the rights of any third party, including copyright, trademark, privacy or other personal or proprietary rights; or
    2. Contain libellous, Prohibited Content or other unlawful material;
  2. Hereby agree to indemnify, defend and hold harmless the RA and all of the RA’s officers, directors, owners, agents, customers/clients, information providers, affiliates, licensors and licensees (collectively, the “Indemnified Parties”) from and against any and all liability and costs, including, without limitation, reasonable advocate’s fees, incurred by the Indemnified Parties in connection with any claim arising out of any breach by the client of these Terms or the foregoing representations, warranties and covenants. The client shall cooperate as fully as reasonably required in the defence of any such claim. The RA reserves the right, at its own expense, to assume the exclusive defence and control of any matter subject to indemnification by the client.

Applicable law: This Website, including the Content and Contributed Content and information contained herein, and the provision of Research Services shall be governed by the Securities and Exchange Board of India, laws of the Republic of India and the courts of Chennai, India which shall retain exclusive jurisdiction to entertain any proceedings in relation to any disputes arising out of the same. As such, the laws of India shall govern any transaction completed using this Website.

Information gathered and tracked: Information submitted or collected on the Website or pursuant to the use of the Services is stored in a database. Specifically, we store the username, name, e-mail address, contact number, as submitted or collected on our Website or through the provision of the Research Services. We may use such information to send out occasional promotional materials, including alerts on new Services available, or other promotional and marketing material relating to our clients and customers.

In accordance with the Information Technology Act 2000, the name and the details of the Grievance Officer at PrimeInvestor is provided below:

Mr. Srikanth Meenakshi
PrimeInvestor Financial Research Pvt. Ltd., Registered office: 659, 4th Avenue, D-Sector, Anna Nagar Western Extension, Chennai 600 101.
Email: [email protected]

11. Mandatory notice:

Clients shall be requested to go through Do’s and Don’ts while dealing with RA as specified in SEBI master circular no. SEBI/HO/MIRSD-POD-1/P/CIR/2024/49 dated May 21, 2024 or as may be specified by SEBI from time to time.

12. Optional Centralised Fee Collection Mechanism:

SEBI has operationalized a centralized fee collection mechanism for IA and RA. Under this mechanism, clients shall pay fees to IAs/RAs through a designated platform/portal administered by a recognized Administration and Supervision body. This is an optional mechanism for the registered entities. At this time, PrimeInvestor has opted out of this fee collection mechanism. Therefore, all subscription payments for the Research Services will be through the modes as specified in Clause 5 of these Terms.

Enter the OTP sent to (Edit)
By doing this you agree to our terms & conditions
Didn't receive OTP? Resend

Have an account?
Login To Your Account
OR
Don’t have an account ? Register for free